Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2018-04-16 Proxy Solicitation & In…
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically titled as a Preliminary Proxy Statement for the Annual Meeting of Stockholders of Moleculin Biotech, Inc. It includes detailed information about the annual meeting, proposals to be voted on (such as election of directors, ratification of auditors, reverse stock split, stock plan approval), voting instructions, and governance-related disclosures. It is not a financial report, earnings release, or legal proceeding update. It is a solicitation document for shareholder voting at the annual meeting, which fits the definition of Proxy Solicitation & Information Statement (PSI). The document length is substantial and contains the full proxy statement, not just an announcement or notice, so it is not an RPA or RNS. Therefore, the correct classification is PSI with high confidence.
2018-04-16 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Act of 1933. It is a registration statement for the resale of shares of common stock issuable upon exercise of warrants. The document includes detailed information about the company, the securities being registered, risk factors, use of proceeds, selling shareholders, plan of distribution, and other disclosures typical of an S-1 filing. This type of filing is related to capital raising and securities registration, not an annual report, earnings release, or other report types. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not merely an announcement of a report. Hence, the correct classification is CAP with high confidence.
2018-04-11 English
8-K
Earnings Release Classification · 85% confidence The document is a Form 8-K filing dated March 28, 2018, from Moleculin Biotech, Inc. It reports the issuance of a press release announcing financial results for the year ended December 31, 2017. The text indicates that the actual financial results are contained in the attached press release (Exhibit 99.1), and the 8-K itself is a brief notice of this event. The document length is only 3046 characters, which is quite short and consistent with an announcement rather than a full earnings release. According to the 'Menu vs Meal' rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the correct classification is Earnings Release (ER), as the 8-K is used to announce earnings results, but since the actual financial data is in the press release, and the 8-K is short, it is best classified as ER with moderate confidence. However, since the 8-K includes the press release as an exhibit, and the text references the press release as the source of financial results, the best fit is Earnings Release (ER).
2018-03-28 English
10-K
Annual Report FY 2017
2018-03-28 English
SCHEDULE 13G
Major Shareholding Notification
2018-02-23 English
SABBY 13G MBRX 2.21.18
Major Shareholding Notification
2018-02-21 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.